AzTrials
AzTrials

Healthy VolunteersPhase 1NCT06133478

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

A Phase 1 study testing NUV001 active cohort 1, NUV001 active cohort 2 and NUV001 active cohort 3 in people with Healthy Volunteers, run by Nuvamid SA at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This blinded placebo-controlled study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001 Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Volunteers
What is being tested?
NUV001 active cohort 1, NUV001 active cohort 2 and NUV001 active cohort 3
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
32 participants
Where
1 siteUnited States
Study dates
9 Nov 2023to 5 Apr 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Participants must satisfy all the following inclusion criteria before being allowed to enter the study:
  • Male or female 18 to 55 years of age inclusive, at screening.
  • A body mass index (BMI) between 18.00 and 30.00 kg/m² inclusive and a body weight between 60 kg and 100 kg for males (inclusive), and 50 kg and 100 kg for females (inclusive).
  • Healthy as determined by the investigator based on medical history, physical examination findings, clinical laboratory test results, and digital 12 lead ECG readings (all results should be normal or, if out of range, non-clinically significant as determined by the Investigator).
  • Vital signs at Screening and Admission are within the following ranges:
  • Systolic blood pressure 90-140 mmHg (inclusive);
Show all 26Show fewer
  • Diastolic blood pressure 50-90 mmHg (inclusive);
  • Heart rate 40-100 beats per minute (inclusive);
  • Oral temperature 36.0-37.5°C (inclusive);
  • AST, ALT, and Total bilirubin are <1.5 x ULN Screening and Admission.
  • Serum creatinine is <1.5 mg/dL and estimated glomerular filtration rate is ≥60 mL/min/1.73 m2 based on Chronic Kidney Disease Epidemiology Collaboration at Screening and Admission.
  • QTcF is ≤450 ms for males and ≤470 ms for females at Screening and Admission.
  • Non-smoker and no use of tobacco or nicotine-containing products for 6 months prior to screening.
  • Have a high probability for compliance with and completion of the study.
  • Female participants of childbearing potential [meaning who are not either surgically sterile (bilateral tubal ligation/occlusion, bilateral salpingectomy, bilateral oophorectomy or hysterectomy) or post-menopausal (no spontaneous menstrual periods for at least two years), confirmed by serum follicle stimulating hormone [FSH] in post-menopausal range based on laboratory reference range, must commit to using a highly effective method of birth control and throughout the entire study and for 90 days after last dose of study drug:
  • Combined hormonal estrogen and progestogen-containing, or progestogen-only hormonal contraception associated with inhibition of ovulation, started at least 4 weeks prior to the dosing and condom with spermicide for the male partner.
  • Intrauterine device or intrauterine hormone-releasing system placed at least 4 weeks prior to the dosing, and condom with spermicide for the male partner.
  • Simultaneous use of a diaphragm or cervical cap with intravaginally applied spermicide and, for the male partner, a male condom with spermicide.
  • Sterile male partner, i.e., vasectomized since at least 3 months before dosing.
  • Female participants with same-sex or no partner (when in line with the preferred and usual subject's lifestyle) must agree to use an acceptable form of birth control for duration noted above if they were to become sexually active with a male partner. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
  • NB: Surgically sterile women, if the surgery (bilateral tubal ligation/occlusion, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy) was performed at least 3 months prior to dosing, and female participants who have same-sex sexual relations do not have to use contraception. If the surgery was performed less than 3 months before dosing, the female subject will be considered a woman of childbearing potential (WOCBP).
  • Male participants with a female partner of childbearing potential will be required to be vasectomized at least 3 months prior to screening or use a condom with spermicide throughout the duration of the study and for 90 days after last dose of study drug.
  • Male participants with same-sex or no partner (when in line with the subject's preferred and usual lifestyle) must agree to use an acceptable form of birth control for duration noted above if they were to become sexually active with a female partner of childbearing potential.
  • Agree to avoid sperm or egg donation during the study and for 90 days following last dose of study drug.
  • Can provide a voluntary written informed consent to participate in the study prior to any initiation of study-related procedures.
  • Participant is not subject to any of the following procedures: ward of court, trusteeship, supervision order.

Who cannot join

  • If any of the following exclusion criteria apply, the participant must not enter in the study:
  • Medical History
  • Any significant cardiovascular (e.g., heart failure), hepatic, renal, respiratory (e.g., asthma), gastrointestinal, endocrine (e.g., diabetes, dyslipidemia), immunologic, dermatological, hematological, neurologic, psychiatric disease or history of any clinically important drug allergy.
  • Acute disease state (e.g., vomiting, fever, diarrhea) within 7 days before Day 1 of Treatment Period 1 (SAD).
  • Pregnant or lactating female.
  • Inability to follow study procedures.
Show all 19Show fewer
  • Use of recreational drugs within 1 year before Day 1 of Treatment Period 1 (SAD).
  • History of alcoholism within 1 year before Day 1 of Treatment Period 1 and/or Regular alcohol consumption >14 units of alcohol per week (1 unit = ½ pint [approximately 240 mL] beer, 25 mL of 40% spirit or a 125 mL glass of wine) within 3 months prior to the admission.
  • Donation of blood or blood loss (i.e., > 400 mL) within 90 days before Day 1 of Treatment Period 1 (SAD).
  • Known allergy or intolerance to study drug, or excipients present in drug product.
  • Physical and Laboratory Findings
  • Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibody at Screening.
  • Positive findings of urine drug screen [methadone, barbiturates, oxycodone, amphetamines, methamphetamines, opiates, cannabinoids, cocaine, benzodiazepines, tricyclic antidepressants (TCA), 3,4-methylenedioxy-methamphetamine (MDMA; ecstasy), phencyclidine, cotinine] at screening or admission.
  • Positive Covid -19 by rapid antigen test at admission.
  • Prohibited Treatments and study restrictions:
  • Use of any investigational drug within 30 days before study drug administration on Day 1 of Treatment Period 1 (SAD) except for medications needed to treat Adverse Events.
  • Use of prescription or over the counter (OTC) medications, herbal supplements, antacids, vitamins, minerals or food supplements (especially those containing tryptophane, vitamin B3 (NAM and niacin)) within the previous 14 days or 5 half-lives (whichever is longer) before Day 1 of Treatment Period 1 (SAD) and throughout the study and follow-up visit (except for occasional use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, and oral contraception for females of childbearing potential).
  • Consumption of grapefruit juice, alcoholic beverages or any caffeine-containing products or stimulating beverages containing xanthine derivatives (e.g., coffee, tea, chocolate, or soda) for 48 hours prior to dosing on D1 until D2 (Treatment Period 1 (SAD)) and for 48 hours prior to dosing on D1 until the end of the inpatient period (for Treatment Period (MAD)).
  • Participants will be requested to abstain from strenuous physical activity, for 4 days prior to D1 of each treatment period (SAD/MAD), during confinement for each treatment period and 4 days prior to the follow up visit.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Medpace Clinical Pharmacology Unit

    Cincinnati, Ohio, 45227

Other trials in United States

About this study

Official title: Double-blind, Placebo-controlled, Ascending Single- and Multiple- Dose Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

This blinded placebo-controlled study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001

Read the detailed description

This is a phase I, single-center, double blind, randomized, single- and multiple-dose, study in four (4) cohorts of eight (8) healthy adult male and female participants per period and dose level.

This study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001

The study will consist of a screening period up to 28 days followed by two (2) treatment periods per participant:

  • Treatment Period 1: Single ascending dose (SAD) part with a 3-days inpatient period.
  • Treatment Period 2: Multiple ascending dose (MAD) part with a 16-days inpatient period. Dosing from Period 2 Day 1 to Day 14.

A washout of at least 5 days after the first dosing (Period 1 Day 1) should take place between the two periods. A follow-up visit will take place between 6 to 10 days after last dosing (i.e., D14 in period 2) or early discontinuation.

NUV001 will be given orally at four dose levels. Each participant will undergo two treatment periods, but they will receive only one dose level.

The decision to proceed to subsequent dosing cohorts will be made based on a blinded review of the emerging safety data and available PK data.

Being tested
NUV001 active cohort 1, NUV001 active cohort 2, NUV001 active cohort 3, NUV001 active cohort 4, NUV001 placebo cohort 1
Keywords
Phase 1, Single ascending dose (SAD), Multiple ascending dose (MAD), Safety, Tolerance, Pharmacokinetics

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NUV001 active cohort 1Drug

    Also called NUV001 A mg

    6 participants will be assigned to receive active treatment

  • NUV001 active cohort 2Drug

    Also called NUV001 B mg

    6 participants will be assigned to receive active treatment

  • NUV001 active cohort 3Drug

    Also called NUV001 C mg

    6 participants will be assigned to receive active treatment

  • NUV001 active cohort 4Drug

    Also called NUV001 D mg

    6 participants will be assigned to receive active treatment

  • NUV001 placebo cohort 1Drug

    2 participants will be assigned to receive placebo

  • NUV001 placebo cohort 2Drug

    2 participants will be assigned to receive placebo

  • NUV001 placebo cohort 3Drug

    2 participants will be assigned to receive placebo

  • NUV001 placebo cohort 4Drug

    2 participants will be assigned to receive placebo

Study groups in NCT06133478
Study groupRoleWhat they receive
NUV001 activeExperimentalSingle oral administration (treatment period 1 - SAD) and after a washout of at least 5 days, repeated once daily (q.d.) administrations for 14 days (treatment period 2 - MAD)
Receives: Drug: NUV001 active cohort 1; Drug: NUV001 active cohort 2; Drug: NUV001 active cohort 3; Drug: NUV001 active cohort 4
NUV001 PlaceboPlacebo comparatorSingle oral administration (treatment period 1 - SAD) and after a washout of at least 5 days, repeated once daily (q.d.) administrations for 14 days (treatment period 2 - MAD)
Receives: Drug: NUV001 placebo cohort 1; Drug: NUV001 placebo cohort 2; Drug: NUV001 placebo cohort 3; Drug: NUV001 placebo cohort 4

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety as measured by subject incidence of treatment-emergent adverse events (SAD/MAD)

    Percentage of Participants Who Experienced Any Adverse Events.

    Measured: SAD: First dose date (treatment period 1 Day 1) plus 1 day (until discharge), MAD: First dose date (treatment period 2 Day 1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).

  2. Safety as measured by subject incidence of treatment-emergent clinically significant changes in vital signs (SAD/MAD)

    Subject incidence of treatment-emergent clinically significant changes in vital signs (Systolic and Diastolic Blood Pressure in millimeters of mercury (mmHg), Heart Rate in beats per minute (bpm), and Oral Body temperature in Celsius).

    Measured: SAD: First admission (treatment period 1 Day -1) until discharge (treatment period 1 Day 2); MAD: Second admission (treatment period 2 Day -1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).

  3. Safety as measured by subject incidence of treatment-emergent clinically significant changes in Electrocardiograms (SAD/MAD)

    Subject incidence of treatment-emergent clinically significant changes in 12-lead ECGs (PR interval in milliseconds (msec), QRS duration in milliseconds (msec), QRS axis in milliseconds (msec), QT interval in milliseconds (msec)).

    Measured: SAD: First admission (treatment period 1 Day -1) until discharge (treatment period 1 Day 2); MAD: Second admission (treatment period 2 Day -1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).

  4. Safety as measured by subject incidence of treatment-emergent clinically significant changes in Blood safety tests (SAD/MAD)

    Subject incidence of treatment-emergent clinically significant changes in clinical laboratory safety tests (Complete Blood Count (absolute counts and %), Fasting blood glucose concentration and Serum concentrations in Electrolytes, Protein, Albumin, Total Bilirubin, Blood urea nitrogen, Creatinine, Aspartate Aminotransferase, Alanine Aminotransferase, estimated Glomerular Filtration Rate (eGFR using CKD EPI equation, Activated partial thromboplastin time (aPTT) and Prothrombin Time test (PT) with International Normalized Ratio (INR)).

    Measured: SAD: First admission (treatment period 1 Day -1) until discharge (treatment period 1 Day 2); MAD: Second admission (treatment period 2 Day -1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).

  5. Safety as measured by subject incidence of treatment-emergent clinically significant changes in Urinalysis safety tests (SAD/MAD)

    Subject incidence of treatment-emergent clinically significant changes in Urinalysis safety tests (pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase).

    Measured: SAD: First admission (treatment period 1 Day -1) until discharge (treatment period 1 Day 2); MAD: Second admission (treatment period 2 Day -1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).

  6. Safety as measured by subject incidence of treatment-emergent clinically significant changes in Weight (SAD/MAD)

    Subject incidence of treatment-emergent clinically significant changes in Weight in kilograms (Kg).

    Measured: SAD: First admission (treatment period 1 Day -1) until discharge (treatment period 1 Day 2); MAD: Second admission (treatment period 2 Day -1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).

Secondary outcomes (6)

  1. NUV001 concentration in whole blood (SAD/MAD)

    Evolution from baseline of NUV001 concentration in whole blood

    Measured: Treatment period 1 (SAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Day 1; Treatment period 2 (MAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Days 1 and 14 and Predose on Days 4, 8 and 12

  2. NUV001 metabolite A concentration in whole blood (SAD/MAD)

    Evolution from baseline of NUV001 metabolite A concentration in whole blood

    Measured: Treatment period 1 (SAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Day 1; Treatment period 2 (MAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Days 1 and 14 and Predose on Days 4, 8 and 12

  3. NUV001 metabolite B concentration in plasma (SAD/MAD)

    Evolution from baseline of NUV001 metabolite B concentration in plasma

    Measured: Treatment period 1 (SAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Day 1; Treatment period 2 (MAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Days 1 and 14 and Predose on Days 4, 8 and 12

  4. NUV001 metabolite C concentration in plasma (SAD/MAD)

    Evolution from baseline of NUV001 metabolite C concentration in plasma

    Measured: Treatment period 1 (SAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Day 1; Treatment period 2 (MAD) : Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours after dosing on Days 1 and 14 and Predose on Days 4, 8 and 12

  5. NUV001 metabolite C concentration in urine (SAD/MAD)

    Evolution from baseline of NUV001 metabolite C concentration in urine

    Measured: Treatment period 1 (SAD) : collection at Predose and during intervals 0-6, 6-12 and 12-24 hours on Day 1 ; Treatment period 2 (MAD) : collection at Predose and during intervals 0-6, 6-12 and 12-24 hours on Days 1 and 14

  6. NUV001 metabolite D concentration in urine (SAD/MAD)

    Evolution from baseline of NUV001 metabolite D concentration in urine

    Measured: Treatment period 1 (SAD) : collection at Predose and during intervals 0-6, 6-12 and 12-24 hours on Day 1 ; Treatment period 2 (MAD) : collection at Predose and during intervals 0-6, 6-12 and 12-24 hours on Days 1 and 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2023
  2. Study start9 Nov 2023
  3. Primary completion1 Mar 2024
  4. Study completion5 Apr 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06133478
Sponsor's protocol ID
NUV 001-CLI-001
Status last verified
May 2024
First submitted
10 Nov 2023
Last updated
28 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing NUV001 active cohort 1, NUV001 active cohort 2 and NUV001 active cohort 3 in people with Healthy Volunteers, run by Nuvamid SA at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 26 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety as measured by subject incidence of treatment-emergent adverse events (SAD/MAD) (time frame: SAD: First dose date (treatment period 1 Day 1) plus 1 day (until discharge), MAD: First dose date (treatment period 2 Day 1) up to discharge (treatment period 2 Day 15) plus 10 days (follow up visit).). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06133478.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in